title: Reply.
authors.affiliation: Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; Weill-Cornell Medical Center, New York, New York. Electronic address: francij1@mskcc.org.
authors.forename: Jasmine H
authors.initials: JH
authors.lastname: Francis
authors.affiliation: Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; Weill-Cornell Medical Center, New York, New York.
authors.forename: David H
authors.initials: DH
authors.lastname: Abramson
authors.affiliation: Jules-Gonin Eye Hospital, Lausanne, Switzerland.
authors.forename: Marie-Claire
authors.initials: MC
authors.lastname: Gaillard
authors.affiliation: Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; Weill-Cornell Medical Center, New York, New York.
authors.forename: Brian P
authors.initials: BP
authors.lastname: Marr
authors.affiliation: Pediatric Hematology Oncology Unit, University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors.forename: Maja
authors.initials: M
authors.lastname: Beck-Popovic
authors.affiliation: Jules-Gonin Eye Hospital, Lausanne, Switzerland.
authors.forename: Francis L
authors.initials: FL
authors.lastname: Munier
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D005134:Eye Neoplasms / Q000145:classification*; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage*; D009366:Neoplasm Seeding; D019572:Retinal Neoplasms / Q000145:classification*; D012175:Retinoblastoma / Q000145:classification*; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan